Unlock instant, AI-driven research and patent intelligence for your innovation.

Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain (PLAD) of tumor necrosis factor receptors

A PLAD, receptor technology, applied in cytokine/lymphokine/interferon receptors, receptors/cell surface antigens/cell surface determinants, animal/human proteins, etc.

Inactive Publication Date: 2008-09-24
GOVERNMENT OF THE US SEC THE DEPT OF HEALTH & HUMAN SERVICES NAT INST OF HEALTH
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the etiology and pathogenesis of RA are not fully understood, cytokines such as TNF-α, IL-1, IL-6, and receptor activator of NF-κB ligand (RANKL) are implicated in disease progression (56-60)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain (PLAD) of tumor necrosis factor receptors
  • Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain (PLAD) of tumor necrosis factor receptors
  • Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain (PLAD) of tumor necrosis factor receptors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0195] H9 lymphoma cells were washed and resuspended in PBS. Cells were then incubated with 100 ng / ml human recombinant TNFα (R&D Systems) under rotation for 1 hour at 4°C. Cells were then treated with 2 mM crosslinker DTSSP (Pierce) for 30 minutes and the reaction was stopped with 20 mM Tris.Cl [pH 7.5] for 15 minutes on ice. Cells were lysed with 150 mM NaCl, 20 mM Tris.Cl [pH 7.5], 1 mM EDTA, 30 mM NaF, 2 mM b-glycerol phosphate and 1 mM sodium orthovanadate supplemented with protease inhibitors (Boehringer Mannheim). Equal amounts of lysates were electrophoresed under non-reducing (without β-mercaptoethanol) or reducing (with 280 mM β-mercaptoethanol) conditions and analyzed for p60 and p80 complexes with specific antibodies (19). Densitometric analysis was performed with a Kodak Image Station 440.

[0196] The p80 complex was found to show a molecular size approximately three times larger than the unit size, consistent with glycosylated and unglycosylated trimers ( Fig...

Embodiment II

[0213] In human autoimmune lymphoproliferative syndrome (ALPS), heterozygous mutations encoding an abnormal form of Fas (CD95 / APO-1) interfere dominantly with Fas-induced lymphocyte apoptosis. The present invention demonstrates that this arises from pre-association of wild-type and mutant Fas receptors utilizing the extracellular domain, independent of ligand-induced receptor oligomerization. The pre-associated Fas receptor complex was found to be required for signal transduction and confirmed in living cells by the novel application of FRET between green fluorescent protein (GFP) variants body. These results provide a new molecular mechanism for Fas signaling and dominant interference in human disease.

[0214] Fas(APO-1 / CD95) is a cell surface receptor that transduces apoptotic signals critical for immune homeostasis and tolerance (19-21). Fas is a 317 amino acid type 1 membrane glycoprotein with three cysteine-rich extracellular domains (CRDs) that are characteristic of t...

Embodiment III

[0229] method

[0230] Mice and Reagents

[0231] BALB / c, C57BL / 6, DBA / 1J, C3H / HeJ, C3H / HeN, TNFR1 and TNFR2 knockout mice were purchased from Jackson Laboratory. TNF-α transgenic mice were purchased from Taconic. Male mice aged 6-8 weeks were used in all experiments and housed in the animal room of the Immunology Laboratory (NIAID, NIH). CpG DNA was synthesized using CBER. The CpG DNA 1668 sequence is 5'-TCCATGACGTTCCTGATGCT-3' (SEQ ID NO: 61) (50). Anti-P60(1H11) or anti-P80PLAD(3H11) mouse monoclonal antibody (MAb) was prepared by using P60 PLAD and P80PLAD.

[0232] Purification of PLAD-GST fusion protein

[0233]Cloning and purification of the PLAD-GST fusion protein was performed as described in the literature (78). Purified PLAD-GST fusion proteins were verified by 4-20% Tris-glycine gels and mass spectrometry and stored at -80°C. LPS was removed with Detoxi-Gel AffinityPak columns (Pierce).

[0234] In vitro testing of P60 and P80 PLAD proteins

[0235] L929 c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a polypeptide comprising the isolated amino acid sequence of a pre-ligand assembly domain (PLAD) of a TNF receptor-like receptor. Also provided by this invention is a polypeptide comprising the isolated amino acid sequence of a pre-ligand assembly domain (PLAD), wherein the PLAD is selected from the group consisting of: the PLAD of a TNF-R, the PLAD of p60, the PLAD of p80, the PLAD of Fas (CD95 / APO-1), the PLAD of TRAIL receptors, the PLAD of LT / ssR, the PLAD of CD40, the PLAD of CD30, the PLAD of CD27, the PLAD of HVEM, the PLAD of OX40 and the PLAD of DR4. TNF-R, p60, p80, Fas, TRAIL receptor, LT / ssR, CD40, CD30, CD27, HVEM, OX40, DR4, TROY, EDAR, XEDAR, DCR3, AITR, 4-1BB, DR3, RANK, TACI, BCMA, DR6, DPG, DR5, DCRl AND DCR2 are all members of the TNF receptor superfamily or the TNF-like receptor family. The invention also provides the PLAD for other members of the TNF receptor superfamily. The polypeptides of the present invention can be utilized to inhibit oligomerization of members of theTNF receptor superfamily. These polypeptides can also be utilized to inhibit ligand binding to members of the TNF receptor superfamily. The present invention also provides a composition comprising an inhibitor of TNF receptor oligomerization. Further provided by this invention are members of the TNF receptor superfamily that are lacking a PLAD.

Description

[0001] This application claims priority based on U.S. Provisional Application No. 60 / 694,015, filed June 24, 2005, and U.S. Provisional Application No. 60 / 717,589, filed September 16, 2005, the entire contents of which are incorporated herein by reference manual. technical field [0002] The present invention provides a new function of the conserved extracellular region domain of TNF receptor (TNFR) superfamily members in mediating specific ligand-independent assembly of receptor oligomers. Background technique [0003] Members of the TNFR superfamily typically contain 1 to 6 cysteine-rich domains (CRDs) of the extracellular domain, a single transmembrane domain, and an intracytoplasmic domain of variable size. Members of this receptor family generally bind ligands of the TNF family of cytokines defined by structural, functional and sequence similarity. These receptors form trimers in their active liganded state, and some members contain a cytoplasmic domain known as the de...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/715
Inventor M·莱纳多G-M·邓F·K-M·陈L·郑
Owner GOVERNMENT OF THE US SEC THE DEPT OF HEALTH & HUMAN SERVICES NAT INST OF HEALTH